| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9938 | Lusutrombopag（S-888711） Featured | Lusutrombopag（S-888711） is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. |
|
| DC7456 | LX1606 Hippurate Featured | LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity. |
|
| DC10765 | LX-2761 | LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control. |
|
| DC7921 | Sotagliflozin (LX-4211) Featured | LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents. |
|
| DC10828 | LXH254 Featured | LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor. |
|
| DC2072 | LXR623 Featured | LXR-623 is a novel Liver X Receptor modulator |
|
| DC6306 | LY2157299(Galunisertib) Featured | LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2. |
|
| DC8630 | Ralimetinib 2MsOH(LY2228820) Featured | LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively). |
|
| DC10782 | LY2510924 Featured | LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. |
|
| DC7943 | LYS6K2(LY2584702) tosylate salt Featured | LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes. |
|
| DC7103 | LY2603618(IC-83) Featured | LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials. |
|
| DC7993 | Prexasertib (LY2606368) 2HCl Featured | LY2606368 2Hcl is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
|
| DC10796 | Prexasertib (LY2606368) Featured | LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
|
| DC7665 | Gandotinib(LY2784544) Featured | LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2. |
|
| DC5180 | LY2811376 Featured | LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM. |
|
| DC7019 | LY-2874455 Featured | LY2874455 is a novel and potent FGF/FGFR inhibitor. |
|
| DC5053 | LY2886721 Featured | LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease. |
|
| DC11681 | LY2922470 | LY2922470 (LY-2922470) is a potent, selective, orally available GPR40 agonist with EC50 of 7 nM. |
|
| DC7191 | LY-2940680(Taladegib) Featured | LY2940680 binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. |
|
| DC8344 | LY3009120 Featured | LY3009120 is a potent and selective pan-RAF inhibitor with potential anticancer activity. |
|
| DC10219 | LY3023414 Featured | LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
|
| DC7776 | LY-3039478 | LY3039478 a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested. |
|
| DC10675 | LY3200882 Featured | LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor. |
|
| DC10640 | LY3214996 Featured | LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines. |
|
| DC12261 | LY3295668 (AK-01) | LY3295668 is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively. |
|
| DC8523 | LY333531 Hydrochloride(Ruboxistaurin HCl) Featured | LY-333,531 Hydrochloride is a potent, selective inhibitor of Protein Kinase C isozymes, PKC beta I (IC50 = 4.7 nM) and PKC beta II (IC50 = 5.9 nM). It is potentially beneficial for cancer research. |
|
| DC2018 | LY335979 (Zosuquidar 3HCl) Featured | LY335979 (Zosuquidar) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM. |
|
| DC11323 | LY354740 | LY354740 is an agonist of the group II metabotropic glutamate receptor (mGluR) subtypes mGluR2 and mGluR3 (Kis = 99 and 94 nM, respectively). |
|
| DC7192 | LY-404039 Featured | LY404039 is an inhibitor for mGluR1(Ki=149 nM) and mGluR2(Ki= 92 nM), which can also inhibit dopamine receptor. |
|
| DC5036 | LY-411575 Featured | LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM. |
|
